Molecular mechanisms of pediatric cardiomyopathies and new targeted therapies

Progress in Pediatric Cardiology

Volumn 25, Issue 1, 2008, Pages 3-21

  Towbin, Jeffrey A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Cardiomyopathies; Disruption; Mechanism; Therapies

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CARVEDILOL; CONNECTIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LAMIN A; LAMIN C; LOSARTAN; METOPROLOL; MYOSIN BINDING PROTEIN C; MYOSIN SUBFRAGMENT; PROPRANOLOL;

ARTICLE; AUTOSOMAL DOMINANT INHERITANCE; BARTH SYNDROME; CARDIOMYOPATHY; CLINICAL FEATURE; CONGESTIVE CARDIOMYOPATHY; DANON DISEASE; DRUG TARGETING; FABRY DISEASE; FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; GENE IDENTIFICATION; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; GLYCOGEN STORAGE DISEASE TYPE 2; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; KEARNS SAYRE SYNDROME; MERRF SYNDROME; MITOCHONDRION; MOLECULAR BIOLOGY; MOLECULAR GENETICS; MUSCLE CELL; MYOFILAMENT; PEDIATRICS; PRIORITY JOURNAL; THIN FILAMENT; TREATMENT OUTCOME; X CHROMOSOME LINKED DISORDER;

EID: 40949131738     PISSN: 10589813     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ppedcard.2007.11.001     Document Type: Article

References (200)

1. Towbin J., and Bowles N. Cardiomyopathy. In: McMillian J.A., Feigin R.A., DeAngelis C.D., and Jones Jr. M.D. (Eds). Oski's Pediatrics. Principles & Practice. 4th Edition (2005), Lippincott Williams & Wilkins, Philadelphia, PA 1624-1648 Chapter 283
2. Abelman W., and Lorrell B. The challenge of cardiomyopathy. J Am Coll Cardiol 13 (1989) 1219
3. Towbin JA. Hypertrophic Cardiomyopathy. 2005. In: Heart Failure in Children and Young Adults. From Molecular Mechanisms to Medical and Surgical Strategies. Chang AC, Towbin JA, editors. Saunders Elsevier, Inc., Philadelphia, PA, 2006, Chapter 20, pp. 278-297.
4. Towbin J., and Bowles N. The failing heart. Nature 415 (2002) 227-233
5. Morita H., and Seidman C. Genetic causes of human heart failure. J Clin Invest 115 (2005) 518-526
6. Maron B., Towbin J., Thiene G., et al., American Heart Association, Council on Clinical Cardiology, Heart Failure and Transplantation Committee, Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups, Council on Epidemiology and Prevention. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 113 (2006) 1807-1816
7. Schwartz SM, Duffy JY, Pearl JM, Nelson DP. Cellular and molecular aspects of myocardial dysfunction. 2001;29:S214-S219.
8. Gregorio C., and Antin P. To the heart of myofibril assembly. Trends Cell Biol 10 (2000) 355-362
9. Clark K., McElhinny A., Beckerle M., and Gregorio C. Striated muscle cytoarchitecture: an intricate web of form and function. Annu Rev Cell Dev Biol 18 (2002) 637-706
10. Vigoreaux J. The muscle Z band: lessons in stress management. J Muscle Res Cell Motil 15 (1994) 237-255
11. Barth A., Nathke I., and Nelson W. Cadherins, catenins and APC protein; interplay between cytoskeletal complexes and signaling pathways. Curr Opin Cell Biol 9 (1997) 683-690
12. Capetanaki Y. Desmin cytoskeleton: a potential regulator of muscle mitochondrial behaviour and function. Trends Cardiovasc Med 12 (2002) 339-348
13. Sharp W., Simpson D., Borg T., Samarel A., and Terracio L. Mechanical forces regulate focal adhesion and costamere assembly in cardiac myocytes. Am J Physiol 273 (1997) H546-H556
14. Straub V., and Campbell K. Muscular dystrophies and the dystrophin-glycoprotein complex. Curr Opin Neurol 10 (1997) 168-175
15. Furukawa T, Ono Y, Tsuchiya H, et al. 2001. Specific interaction of the potassium channel beta-subunit iph with the sarcomeric protein T-cap suggests a T-tubule-myofibril linking system. 313:775-784.
16. Kucera J., Rohr S., and Rudy Y. Localization of sodium channels in intercalated disks modulates cardiac conduction. Circ Res 91 (2002) 1176-1182
17. Towbin J., Lowe A., Colan S., et al. Incidence, causes, and outcome of dilated cardiomyopathy. JAMA 296 (2006) 1867-1876
18. Michels V., Moll P., Miller F., et al. The frequency of familial dilated cardiomyopathy in a series of patients with idiopathic dilated cardiomyopathy. N Engl J Med 326 (1992) 77-82
19. Berko B., and Swift M. X-linked dilated cardiomyopathy. N Engl J Med 316 (1987) 1186-1191
20. Towbin J., Bowles K., and Bowles N. Etiologies cardiomyopathy and heart failure. Nat Med 5 (1999) 266-267
21. Towbin J., Hejtmancik J., Brink P., et al. X-linked dilated cardiomyopathy (XLCM): Molecular genetic evidence of linkage to the Duchenne muscular dystrophy gene at the Xp21 locus. Circulation 87 (1993) 1854-1865
22. Muntoni F., Cau M., Ganau A., et al. Brief report: deletion of the dystrophin muscle-specific promoter region associated with X-linked dilated cardiomyopathy. N Engl J Med 329 (1993) 921-925
23. Cox G., and Kunkel L. Dystrophies and heart disease. Curr Opin Cardiol 12 (1997) 329-343
24. Hoffman E., Brown R., and Kunkel L. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51 (1987) 919-928
25. Meng H., Leddy J., Frank J., Holland P., and Tuana B. The association of cardiac dystrophin with myofibrils/z-discs regions in cardiac muscle suggests a novel role in the contractile apparatus. J Biol Chem 271 (1996) 12364-12371
26. Kaprielian R., Stevenson S., Rothery S., Cullen M., and Severs N. Distinct patterns of dystrophin organization in myocyte sarcolemma and transverse tubules of normal and diseased human myocardium. Circulation 101 (2000) 2586-2594
27. Koenig M., Hoffman E., Bertelson C., et al. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 50 (1987) 509-517
28. Petrof B., Shrager J., Stedman H., Kelly A., and Sweeny H. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc Natl Acad Sci U S A 90 (1993) 3710-3714
29. Campbell K. Three muscular dystrophies: loss of cytoskeleton-extracellular matrix linkage. Cell 80 (1995) 675-679
30. Klietsch R., Ervasti J., Arnold W., Campbell K., and Jorgensen A. Dystrophin-glycoprotein complex and laminin colocalize to the sarcolemma and transverse tubules of cardiac muscle. Circ Res 72 (1993) 349-360
31. Ozawa E., Yoshida M., Suzuki A., Mizuno Y., Hagiwara Y., and Noguchi S. Dystrophin-associated proteins in muscular dystrophy. Hum Mol Genet 4 (1995) 1711-1716
32. Emery A. The muscular dystrophies. Lancet 359 (2002) 687-695
33. Davies K., and Nowak K. Molecular mechanisms of muscular dystrophies: old and new players. Nat Rev Mol Cell Biol 7 (2006) 762-773
34. Towbin J. The role of cytoskeletal proteins in cardiomyopathies. Curr Opin Cell Biol 10 (1998) 131-139
35. Bowles N., Bowles K., and Towbin J. The "Final Common Pathway" hypothesis and inherited cardiovascular disease: the role of cytoskeletal proteins in dilated cardiomyopathy. Herz 25 (2000) 168-175
36. Feng J., Yan J., Buzin C., Towbin J., and Sommer S. Mutations in the dystrophin gene are associated with sporadic dilated cardiomyopathy. Mol Genet Metab 77 (2002) 119-126
37. Feng J., Yan J., Buzin C., Sommer S., and Towbin J. Comprehensive mutation scanning of the dystrophin gene in patients with nonsyndromic X-linked dilated cardiomyopathy. J Am Coll Cardiol 40 (2002) 1120-1124
38. Neustein H., Lurie P., Dahms B., and Takahashi M. An X-linked recessive cardiomyopathy with abnormal mitochondria. Pediatrics 64 (1979) 24-29
39. Barth P., Scholte H., Berden J., et al. An X-linked mitochondrial disease affecting cardiac muscle, skeletal muscle and neutrophil leucocytes. J Neurol Sci 62 (1983) 327-355
40. Kelley R., Cheatham J., Clark B., et al. X-linked dilated cardiomyopathy with neutropenia, growth retardation, and 3-methylglutaconic aciduria. J Pediatr 119 (1991) 738-747
41. Schlame M., Towbin J., Heerdt P., Jehle R., DiMauro S., and Blanck T. Deficiency of tetralinoleoyl-cardiolipin in Barth syndrome. Ann Neurol 51 (2002) 634-637
42. Bione S., D'Adamo P., Maestrini E., Gedeon A., Bolhuis P., and Toniolo D. A novel X-linked gene, G4.5, is responsible for Barth syndrome. Nat Genet 12 (1996) 385-389
43. Bleyl S., Mumford B., Thompson V., et al. Neonatal, lethal noncompaction of the left ventricular myocardium is allelic with Barth syndrome. Am J Hum Genet 61 (1997) 868-872
44. Graber H., Unverferth D., Baker P., Ryan J., Baba N., and Wooley C. Evolution of hereditary cardiac conduction and muscle disorder: a study involving a family with 6 generations affected. Circulation 74 (1986) 21-35
45. Tsubata S., Bowles K., Vatta M., et al. Mutations in the human delta-sarcoglycan gene in familial and sporadic dilated cardiomyopathy. J Clin Invest 106 (2000) 655-662
46. Karkkainen S., and Peuhkurinen K. Genetics of dilated cardiomyopathy. Ann Med 32 (2007) 91-107
47. Towbin J., and Bowles N. Dilated cardiomyopathy: a tale of the cytoskeleton and beyond. J Cardiovasc Electrophysiol 17 (2006) 919-926
48. Olson T., Michels V., Thibodeau S., Tai Y., and Keating M. Actin mutations in dilated cardiomyopathy, a heritable form of heart failure. Science 280 (1998) 750-752
49. Kamisago M., Sharma S., DePalma S., et al. Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy. N Engl J Med 343 (2000) 1688-1696
50. Li D., Tapscott T., Gonzalez O., et al. Desmin mutations responsible for idiopathic dilated cardiomyopathy. Circulation 100 (1999) 461-464
51. Fatkin D., and Graham R. Molecular mechanisms of inherited cardiomyopathies. Physiol Rev 82 (2002) 945-980
52. Ozawa E., Mizumo Y., Hagiwara Y., Sasaoka T., and Yoshida M. Molecular and cellular biology of the sarcoglycan complex. Muscle Nerve 32 (2005) 563-576
53. Coral-Vazquez R., Cohn R., Moore S., et al. Disruption of the sarcoglycan-sarcospan complex in vascular smooth muscle: a novel mechanism for cardiomyopathy and muscular dystrophy. Cell 98 (1999) 465-474
54. Wheeler M., Allikian M., Heydemann A., Hadhazy M., Zarnegar S., and McNally E. Smooth muscle cell-extrinsic vascular spasms arise from cardiomyocyte degeneration in sarcoglycan-deficient cardiomyopathy. J Clin Invest 113 (2004) 668-675
55. Sakamoto A., Ono K., Abe M., et al. Both hypertrophic and dilated cardiomyopathies are caused by mutation of the same gene, delta-sarcoglycan, in hamster: an animal model of disrupted dystrophin-associated glycoprotein complex. Proc Natl Acad Sci U S A 94 (1997) 13873-13878
56. Olson T., Illenberger S., Kishimoto N., Huttelmaier S., Keating M., and Jockusch B. Metavinculin mutations alter actin interaction in dilated cardiomyopathy. Circulation 105 (2002) 431-437
57. Maeda M., Holder E., Lowes B., Valent S., and Bies R. Dilated cardiomyopathy associated with deficiency of the cytoskeletal protein metavinculin. Circulation 95 (1997) 17-20
58. Chang A., and Potter J. Sarcomeric protein mutations in dilated cardiomyopathy. Heart Fail Rev 10 (2005) 225-235
59. Schmitt J., Kamisago M., Asahi M., et al. Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science 299 (2003) 1410-1413
60. Haghighi K., Kolokathis F., Pater L., et al. Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. J Clin Invest 111 (2003) 869-876
61. Murphy R., Mogensen J., Shaw A., et al. Novel mutation in cardiac troponin I in recessive idiopathic dilated cardiomyopathy. Lancet 363 (2004) 371-372
62. Olson T., Kishimoto N., Whitby F., and Michels V. Mutations that alter the surface charge of alpha-tropomyosin are associated with dilated cardiomyopathy. J Mol Cell Cardiol 33 (2001) 723-732
63. Pyle W., and Solaro R. At the crossroads of myocardial signaling: the role of Z-discs in intracellular signaling and cardiac function. Circ Res 94 (2004) 296-305
64. Knoll R., Hoshijima M., Hoffman H., et al. The cardiac mechanical stretch sensor machinery involves a Z disc complex that is defective in a subset of human dilated cardiomyopathy. Cell 11 (2002) 943-955
65. Arber S., Hunter J., Ross Jr. J., et al. MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure. Cell 88 (1997) 393-403
66. Zolk O., Caroni P., and Bohm M. Decreased expression of the cardiac LIM domain protein MLP in chronic human heart failure. Circulation 101 (2000) 2674-2677
67. Katz A. Cytoskeletal abnormalities in the failing heart. Out on a LIM?. Circulation 101 (2000) 2672-2673
68. Zhou Q., Chu P., Huang C., et al. Ablation of cypher, a PDZ-LIM domain Z-line protein, causes a severe form of congenital myopathy. J Cell Biol 155 (2001) 605-612
69. Granzier H., and Labeit S. The grant protein titin: a major player in myocardial mechanics, signaling, and disease. Circ Res 94 (2004) 284-295
70. Gerul B., Gramlich M., Atherton J., et al. Mutations of TTN encoding the giant muscle filament titin, cause familial dilated cardiomyopathy. Nat Genet 30 (2002) 201-204
71. Fatkin D., MacRae C., Sasaki T., et al. Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. N Engl J Med 34 (1999) 1715-1724
72. Brodsky G., Muntoni F., Miocic S., Sinagra G., Sewry C., and Mestroni L. Lamin A./C gene mutation associated with dilated cardiomyopathy with variable skeletal muscle involvement. Circulation 101 (2000) 473-476
73. Stuurman N., Heins S., and Aebi U. Nuclear lamins: their structure, assembly and interactions. J Struct Biol 122 (1998) 42-66
74. Bonne G., DiBarletta M., Varnous S., et al. Mutations in the gene encoding lamin A/C cause autosomal dominant Emery-Dreifuss muscular dystrophy. Nat Genet 21 (1999) 285-288
75. Di Barletta R., Ricci E., Galluzzi G., et al. Different mutations in the LMNA gene cause autosomal dominant and autosomal recessive Emery-Dreifuss muscular dystrophy. Am J Hum Genet 66 (2000) 1407-1412
76. Muchir A., Bonne G., van der Kooi A., et al. Identification of mutations in the gene encoding lamin A/C in autosomal dominant limb girdle muscular dystrophy with atrioventricular conduction disturbance (LGMD1B). Hum Mol Genet 9 (2000) 1453-1459
77. Decostre V., Ben Yaou R., and Bonne G. Laminopathies affecting skeletal and cardiac muscles: clinical and pathological aspects. Acta Myol 24 (2005) 104-109
78. Taylor M., Slavov D., Gajewski A., Vlcek S., Ku L., Fain P., et al. Thymopoietin (lamina-associated polypeptide 2) gene mutation associated with dilated cardiomyopathy. Hum Mutat 26 (2005) 566-574
79. Badorff C., Lee G.-H., Lamphear B., et al. Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat Med 5 (1999) 320-326
80. Xiong D., Lee G., Badorff C., et al. Dystrophin deficiency markedly increases enterovirus-induced cardiomyopathy: a genetic predisposition to viral heart disease. Nat Med 8 (2002) 872-877
81. Vatta M., Stetson S., Perez-Verdra A., et al. Molecular remodeling of dystrophin in patients with end-stage cardiomyopathies and reversal for patients on assist device therapy. Lancet 359 (2000) 936-941
82. Vatta M., Stetson S., Jimenez S., et al. Molecular normalization of dystrophin in the failing left and right ventricle of patients treated with either pulsatile or continuous flow-type ventricular assist devices. J Am Coll Cardiol 43 (2004) 811-817
83. Maron B. Hypertrophic cardiomyopathy: a systemic review. JAMA 287 (2002) 1308-1320
84. Elliott P., and McKenna W. Hypertrophic cardiomyopathy. Lancet 363 (2004) 188-189
85. Colan S., Lipshultz S., Lowe A., et al. Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: findings from the Pediatric Cardiomyopathy Registry. Circulation 115 (2007) 773-781
86. McKenna W., and Behr E. Hypertrophic cardiomyopathy: management, risk stratification, and prevention of sudden death. Heart 87 (2002) 169-176
87. Frenneaux M. Assessing the risk of sudden cardiac death in a patient with hypertrophic cardiomyopathy. Heart 90 (2004) 570-575
88. Maron B., Carney K., Lever H., et al. Relationship of race to sudden cardiac death in competitive athletes with hypertrophic cardiomyopathy. J Am Coll Cardiol 41 (2003) 974-980
89. Maron B. Hypertrophic cardiomyopathy and sudden death: new perspective on risk stratification and prevention with the implantable cardioverter-defibrillator. Eur Heart J 21 (2000) 1979-1983
90. Spirito P., Maron B., Bonow R., and Epstein S. Occurrence and significance of progressive left ventricular wall thinning and relative cavity dilation in hypertrophic cardiomyopathy. Am J Cardiol 60 (1987) 123-139
91. Aurigemma G., and Gaasch W. Diastolic heart failure. N Engl J Med 351 (2004) 1097-1105
92. Gaasch W., and Zile M. Left ventricular diastolic dysfunction and diastolic heart failure. Annu Rev Med 55 (2004) 373-394
93. Towbin J., and Lipshultz S. Genetics of neonatal cardiomyopathy. Curr Opin Cardiol 14 (1999) 250-262
94. Vulpian A. Contribution à l'étude des rétrécissements de l'orifice ventriculo-aortique. Arch Physiol 3 (1868) 220-222
95. Watkins H. Genetic clues to disease pathways in hypertrophic and dilated cardiomyopathies. Circulation 107 (2003) 1344-1346
96. Jarcho J., McKenna W., Pare J., et al. Mapping a gene for familial hypertrophic cardiomyopathy to chromosome 14q1. N Engl J Med 321 (1989) 1372-1378
97. Solomon S., Jarcho J., McKenna W., et al. Familial hypertrophic cardiomyopathy is a genetically heterogeneous disease. J Clin Invest 86 (1990) 993-999
98. Watkins H., MacRae C., Thierfelder L., et al. A disease locus for familial hypertrophic cardiomyopathy maps to chromosome 1q3. Nat Genet 3 (1993) 333-337
99. Thierfelder L., MacRae C., Watkins H., et al. A familial hypertrophic cardiomyopathy locus maps to chromosome 15q2. Proc Natl Acad Sci U S A 90 (1993) 6270-6274
100. Carrier L., Hengstenberg C., Beckmann J., et al. Mapping of a novel gene for familial hypertrophic cardiomyopathy to chromosome 11. Nat Genet 4 (1993) 311-313
101. MacRae C., Ghaisas N., Kass S., et al. Familial hypertrophic cardiomyopathy with Wolff-Parkinson-White Syndrome maps to a locus on chromosome 7q3. J Clin Invest 96 (1995) 1216-1220
102. Poetter K., Jiang H., Hassanzadeh S., et al. Mutation in either the essential regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle. Nat Genet 13 (1996) 63-69
103. Kimura A., Harada H., Park J., et al. Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy. Nat Genet 16 (1997) 379-382
104. Mogensen J., Klausen I., Pederson A., et al. α-Cardiac actin is a novel disease gene in familial hypertrophic cardiomyopathy. J Clin Invest 103 (1999) R39-R43
105. Satoh M., Takahashi M., Sakamoto T., Hiroe M., Marumo F., and Kimura A. Structural analysis of the titin gene in hypertrophic cardiomyopathy: identification of a novel disease gene. Biochem Biophys Res Commun 2625 (1999) 411-417
106. Geier C., Perrot A., Ozcelik C., et al. Mutations in the human muscle LIM protein gene in families with hypertrophic cardiomyopathy. Circulation 107 (2003) 1390-1395
107. Mohiddin S., Ahmed Z., Griffith A., et al. Novel association of hypertrophic cardiomyopathy, sensorineural deafness and a mutation in unconventional myosin VI (MYO6). J Med Genet 41 (2004) 309-314
108. Hayashi T., Armimura T., Ueda K., et al. Identification and functional and of caveolin-3 mutation associated with familial hypertrophic cardiomyopathy. Biochem Biophys Res Commun 313 (2004) 178-184
109. Seidman J., and Seidman C. The genetic basis for cardiomyopathy from mutation identification to mechanistic paradigms. Cell 108 (2001) 557-567
110. Towbin J., and Bowles N. The failing heart. Nature 415 (2002) 227-233
111. Schiaffino S., and Reggiani C. Molecular diversity of myofibrillar proteins: gene regulation and functional significance. Physiol Rev 76 (1996) 371-423
112. Gollob M., Green M., Tang A., et al. Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. N Engl J Med 344 (2001) 1823-1831
113. Blair E., Redwood C., Ashrafian H., et al. Mutations in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for a central role of energy compromise in disease pathogenesis. Hum Mol Genet 10 (2001) 1215-1220
114. Arad M., Benson D., Perez-Atayde A., et al. Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. J Clin Invest 107 (2002) 357-362
115. Blair E., Redwood C., de Jesus Oliveira M., et al. Mutations of the light meromyosin domain of the β-myosin heavy chain rod in hypertrophic cardiomyopathy. Circ Res 90 (2002) 263-269
116. 2+ sensitive tension due to partial extraction of C-protein from rat skinned cardiac myocytes and rabbit skeletal muscle fibers. J Gen Physiol 97 (1991) 1141-1163
117. Lees-Miller J., and Helfman D. The molecular basis for tropomyosin isoform diversity. Bioessays 13 (1991) 429-437
118. Mesnard L., Logeart D., Taviaux S., Diriong S., Mercadier J., and Samson F. Human cardiac troponin T: cloning and expression of new isoforms in the normal and failing heart. Circ Res 76 (1995) 687-692
119. Townsend P., Barton P., Yacoub M., and Farza H. Molecular cloning of human cardiac troponin T isoforms: expression in developing and failing heart. J Mol Cell Cardiol 27 (1995) 2223-2236
120. Hunkeler N., Kullman J., and Murphy A. Troponin I isoform expression in human heart. Circ Res 69 (1991) 1409-1414
121. Theis J., Bos J., Bartleson V., et al. Echocardiography-determined septal morphology in Z-disc hypertrophic cardiomyopathy. Biochem Biophys Res Commun 351 (2006) 896-902
122. Osio A., Tan L., Chen S., et al. Myozenin-2 is a novel gene for human hypertrophic cardiomyopathy. Circ Res 100 (2007) 766-768
123. Watkins H., Rosenzweig T., Hwang D., et al. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N Engl J Med 326 (1992) 1108-1114
124. Moolman J., Corfield V., Posen B., et al. Sudden death due to troponin T mutations. J Am Coll Cardiol 29 (1997) 549-555
125. Nakajima-Taniguchi C., Matsui H., Fujio Y., Nagata S., Kishimoto T., and Yamauchi-Takihara K. Novel missense mutation in cardiac troponin T gene found in Japanese patient with hypertrophic cardiomyopathy. J Mol Cell Cardiol 29 (1997) 839-843
126. Bonne G., Carrier L., Bercovici J., et al. Cardiac myosin binding protein-C gene splice acceptor site mutation is associated with familial hypertrophic cardiomyopathy. Nat Genet 11 (1995) 438-440
127. Watkins H., Conner D., Thierfelder L., et al. Mutations in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy. Nat Genet 11 (1995) 434-437
128. Niimura H., Bachinski L., Sangwatanaroj S., et al. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. N Engl J Med 338 (1998) 1248-1257
129. Charron P., Dubourg O., Desnos M., et al. Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to cardiac myosin-binding protein C gene. Circulation 97 (1998) 2230-2236
130. Van Driest S., Ackerman M., Ommen S., et al. Prevalence and severity of "benign" mutations in the β-myosin heavy chain, cardiac troponin T, and α-tropomyosin genes in hypertrophic cardiomyopathy. Circulation 106 (2002) 3085-3090
131. Yoneya K., Okamoto H., Machida M., et al. Angiotensin-converting enzyme gene polymorphism in Japanese patients with hypertrophic cardiomyopathy. Am Heart J 130 (1995) 1089-1093
132. Tesson F., Dufour C., Moolman J., et al. The influence of the angiotensin I converting enzyme genotype in familial hypertrophic cardiomyopathy varies with the disease gene mutation. J Mol Cell Cardiol 29 (1997) 831-838
133. Ortlepp J., Vosberg H., Reith S., et al. Genetic polymorphisms in the rennin-angiotensin-aldosterone system associated with expression of left ventricular hypertrophy in hypertrophic cardiomyopathy: a study of five polymorphic genes in a family with a disease causing mutation in the myosin binding protein C gene. Heart 87 (2002) 270-275
134. Doiuchi J., Hamada M., Ito T., and Kokubu T. Comparative effects of calcium-channel blockers and beta-adrenergic blocker on early diastolic time intervals and A-wave ratio in patients with hypertrophic cardiomyopathy. Clin Cardiol 10 (1987) 26-30
135. Lorell B. Use of calcium channel blockers in hypertrophic cardiomyopathy. Am J Med 78 (1985) 43-54
136. Moran A., and Colan S. Verapamil therapy in infants with hypertrophic cardiomyopathy. Cardiol Young 8 (1998) 310-319
137. Nagueh S., Ommen S., Lakkis N., et al. Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 38 (2001) 1701-1706
138. Maron BJ, Dearani JA, Ommen SR, et al. The case for surgery in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 44:2043-2053.
139. O'Rourke R. Cardiac pacing. An alternative treatment for selected patients with hypertrophic cardiomyopathy and adjunctive therapy for certain patients with dilated cardiomyopathy. Circulation 100 (1999) 786-788
140. Maron B. Appraisal of dual-chamber pacing therapy in hypertrophic cardiomyopathy: too soon for a rush to judgment?. J Am Coll Cardiol 27 (1996) 431-432
141. Begley D., Mohiddin S., and Fananapazir L. Dual chamber pacemaker therapy for mid-cavity obstructive hypertrophic cardiomyopathy. Pacing Clin Electrophysiol 24 (2001) 1639-1644
142. Chang S., Lakkis N., Franklin J., Spencer III W., and Nagueh S. Predictors of outcome after alcohol septal ablation therapy in patients with hypertrophic obstructive cardiomyopathy. Circulation 109 (2004) 824-827
143. Nielsen C., Killip D., and Spencer III W. Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: short-term results in 50 consecutive procedures. Clin Cardiol 26 (2003) 275-279
144. Park T., Lakkis N., Middleton K., et al. Acute effect of nonsurgical septal reduction therapy on regional left ventricular asynchrony in patients with hypertrophic obstructive cardiomyopathy. Circulation 106 (2002) 412-415
145. Hess O., and Sigwart U. New treatment strategies for hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 44 (2004) 2054-2055
146. Cable W., Kolodny E., and Adams R. Fabry disease: impaired autonomic function. Neurology 32 (1982) 498-502
147. Sugie K., Yamamoto A., Murayama K., et al. Clinicopathological features of genetically confirmed Danon disease. Neurology 58 (2002) 1773-1778
148. Yang Z., McMahon C., Smith L., et al. Danon disease as an underrecognized cause of hypertrophic cardiomyopathy in children. Circulation 112 11 (Sep 13 2005) 1612-1617
149. Hers H., van Hoof F., and de Barsy T. Glycogen storage diseases. In: Scriver C.R., Beaudet A.L., Sly W.S., and Valle D. (Eds). The Metabolic Basis of Inherited Disease. 6th Ed. (1989), McGraw-Hill, New York 425-452
150. Towbin J. Molecular genetic aspects of cardiomyopathy. Biochem Med Metab Biol 49 (1993) 283-320
151. D'Ancona G., Wurm J., and Croce C. Genetics of type II glycogenosis: assignment of the human gene for acid α-glucosidase to chromosome 17. Proc Natl Acad Sci U S A 76 (1979) 4526-4529
152. Beratis N., LaBadie G., and Hirschhorn K. Genetic heterogeneity in acid α-glucosidase deficiency. Am J Hum Genet 35 (1983) 21-33
153. Zhong N., Martiniuk F., Tzall S., and Hirschhorn R. Identification of a missense mutation in one allele of a patient with Pompe disease and use of endonuclease digestion of PCR-amplified RNA to demonstrate lack of mRNA expression from the second allele. Am J Hum Genet 49 (1991) 635-645
154. Raben N., Danon M., Gilbert A., et al. Enzyme replacement therapy in the mouse model of Pompe disease. Mol Genet Metab 80 (2003) 159-169
155. Masson C., Cisse I., Simon V., Insalaco P., and Audran M. Fabry disease: a review. Joint Bone Spine 71 (2004) 381-383
156. Colucci W., Lorell B., Schoen F., Warhol M., and Grossman W. Hypertrophic obstructive cardiomyopathy due to Fabry's disease. N Engl J Med 307 (1982) 926-928
157. Becker A., Schoorl R., Balk A., and van der Heide R. Cardiac manifestations of Fabry's disease: report of a case with mitral insufficiency and electrocardiographic evidence of myocardial infarction. Am J Cardiol 36 (1975) 829-835
158. Goldman M., Cantor R., Schwartz M., Baker M., and Desnick R. Echocardiographic abnormalities and disease severity in Fabry's disease. J Am Coll Cardiol 7 (1986) 1157-1161
159. Broadbent J., Edwards W., Gordon H., Hartzler G., and Krawisz J. Fabry cardiomyopathy in the female confirmed by endomyocardial biopsy. Mayo Clin Proc 56 (1981) 623-628
160. Bishop D., Calhoun D., Bernstein H., Hantzopoulos P., Quinn M., and Desnick R. Human alpha galactosidase A: nucleotide sequence of a cDNA clone encoding the mature enzyme. Proc Natl Acad Sci U S A 83 (1986) 4859-4863
161. Eng C., and Desnick R. Molecular basis of Fabry disease. Mutations and polymorphisms in the human α-galactosidase A gene. Hum Mutat 3 (1994) 103-111
162. Okumiya T., Ishii S., Kase R., Sakuraba H., and Suzuki Y. α-galactosidase gene mutations in Fabry disease: heterogeneous expressions of mutant enzyme proteins. Hum Genet 95 (1995) 557-561
163. Nakao S., Takenaka T., Maeda M., et al. An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med 333 (1995) 288-293
164. Linhart A., Palecek T., Bultas J, et al. New insights in cardiac structural changes in patients with Fabry's disease. Am Heart J 139 (2000) 1101-1108
165. Sachdev B., Takenaka T., Teraguchih H., et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 105 (2002) 1407-1411
166. Danon M., Oh S., DiMauro S., et al. Lysosomal glycogen storage disease with normal acid maltase. Neurology 31 (1981) 51-57
167. Nishino I., Fu J., Tanji K., et al. Primary LAMP-2 deficiency causes X-linked vascular cardiomyopathy and myopathy (Danon Disease). Nature 406 (2000) 906-909
168. Charron P, Villard E, Sebillon P, et al. Danon's disease as a cause of hypertrophic cardiomyopathy: A systematic survey. Heart 90:842-846.
169. Cheung P., Salt I., Davies S., Hardie D., and Carling D. Characterization of AMP-activated protein kinase gamma-subunit isoforms and their role in AMP binding. Biochem J 346 (2000) 659-669
170. Kemp B., Mitchelhill K., Stapleton D., Michell B., Chen Z., and Witters L. Dealing with energy demand: the AMP-activated protein kinase. Trends Biochem Sci 24 (1999) 22-25
171. Arad M., Moskowitz I., Patel V., et al. Transgenic mice overexpressing mutant PRKAG2 define the cause of Wolff Parkinson-White syndrome in glycogen storage cardiomyopathy. Circulation 107 (2003) 2850-2856
172. Attardi G. The elucidation of the human mitochondrial genome: a historical perspective. Bioessays 5 (1996) 34-39
173. Wallace D., Zheng X., Lott M., et al. Familial mitochondrial encephalomyopathy (MERRF): genetic, pathophysiological, and biochemical characterization of a mitochondrial DNA disease. Cell 55 (1988) 601-610
174. Wallace D. Mitochondrial DNA mutation and neuromuscular disease. Trends Genet 5 (1989) 9-13
175. Clarke A. Mitochondrial genome: defects, disease, and evolution. J Med Genet 27 (1990) 451-456
176. Grivell L. Small, beautiful and essential. Nature 341 (1989) 569-571
177. Anderson S., Banker A., and Barrell B. Sequence and organization of the human mitochondrial genome. Nature 290 (1981) 457-465
178. Petty R., Harding A., and Morgan-Hughes J. The clinical features of mitochondrial myopathy. Brain 109 (1986) 915-938
179. Leu(UUR) mutation associated with maternally inherited myopathy and cardiomyopathy. J Clin Invest 93 (1994) 1102-1107
180. Vogel H. Mitochondrial myopathies and the role of the pathologist in the molecular era. J Neuropathol Exp Neurol 60 (2001) 217-227
181. Capaldi R., Halphen D., Zhang Y., and Yanamura W. Complexity and tissue specificity of the mitochondrial respiratory chain. J Bioenerg Biomembr 20 (1988) 291-311
182. Ozawa T., Tanaka M., Sugiyama S., et al. Multiple mitochondrial DNA deletions exist in cardiomyocytes of patients with hypertrophic or dilated cardiomyopathy. Biochem Biophys Res Commun 170 (1990) 830-836
183. Scaglia F., Towbin J., Craigen W., et al. Clinical spectrum, morbidity, and mortality in 113 pediatric patients with mitochondrial disease. Pediatrics 114 (2004) 925-931
184. Channer K., Channer J., Campbell M., and Rees J. Cardiomyopathy in Kearns-Sayre syndrome. Br Heart J 59 (1988) 486-490
185. Poulton J., Deadman M., Ramacharan S., and Gardiner R. Germ-line deletions of mtDNA in mitochondrial myopathy. Am J Hum Genet 48 (1991) 649-653
186. CT Moraes, S DiMauro, M Zeviani, et-al. Mitochondrial DNA deletions in progressive external ophthalmoplegia and Kearns-Sayre syndrome, N Engl J Med, 320, 1293-1299.
187. Moraes C., Schon E., DiMauro S., and Miranda A. Heteroplasmy of mitochondrial genomes in clonal cultures from patients with Kearns-Sayre syndrome. Biochem Biopsy Res Commun 160 (1989) 765-771
188. 8344Lys point mutation in myoclonus epilepsy and ragged-red fiber disease. Eur J Hum Genet 1 (1993) 88-95
189. Tanno Y., Yoneda M., Nonaka I., Tanaka K., Miyatake T., and Tsuji S. Quantitation of mitochondrial DNA carrying tRANLys mutation in MERRF patients. Biochem Biophys Res Commun 179 (1991) 880-885
190. Shoffner J., Lott M., Lezza A., Seibel P., Ballinger S., and Wallace D. Myoclonic epilepsy and ragged-red fiber disease (MERRF) is associated with a mitochondrial DNA tRNA(Lys) mutation. Cell 61 (1990) 931-937
191. Ser(UCN) gene detected in a family with MERFF/MELAS overlap syndrome. Biochem Biophys Res Commun 214 (1995) 86-93
192. Silvestri G., Moraes C., Shanske S., Oh S., and DiMauro S. A new mtDNA mutation in the tRNA(Lys) gene associated with myoclonic epilepsy and ragged-red fibers (MERRF). Am J Hum Genet 51 (1992) 1213-1217
193. Fukuhara N. Clinicopathologic features of MERRF. Muscle Nerve 3 (1995) 590-594 J Pediatr 124:224-228
194. Pignatelli R., McMahon C., Dreyer W., et al. Clinical characterization of left ventricular noncompaction in children. A relatively common form of cardiomyopathy. Circulation 108 (2003) 2672-2678
195. Chin T., Perloff J., Williams R., Jue K., and Mohrmann R. Isolated noncompaction of left ventricular myocardium. A study of eight cases. Circulation 82 (1990) 507-513
196. Stollberger C., Finsterer J., and Blazek G. Left ventricular hypertrabeculation/noncompaction and association with additional cardiac abnormalities and neuromuscular disorders. Am J Cardiol 90 (2002) 899-902
197. Stollberger C., and Finsterer J. Left ventricular hypertrabeculation/noncompaction. J Am Soc Echocardiogr 17 (2004) 91-100
198. Ichida F., Hamamichi Y., Miyawaki T., et al. Clinical features of isolated noncompaction of the ventricular myocardium: long-term clinical course, hemodynamic properties and genetic background. J Am Coll Cardiol 34 (1999) 233-240
199. Ichida F., Tsubata S., Bowles K., et al. Novel gene mutations in patients with left ventricular noncompaction or Barth syndrome. Circulation 103 (2001) 1256-1263
200. Vatta M., Mohapatra B., Jimenez S., et al. Mutations in Cypher/ZASP in patients with dilated cardiomyopathy and left ventricular non-compaction. J Am Coll Cardiol 42 (2003) 2014-2027